tirzepatide microdosing protocol I'm starting a new longevity protocol: Tirzepatide, a dual GLP-1/GIP receptor agonist. Here is the existing evidence, my protocol, measurement plan, and what I expect to achieve by this intervention. 🧵 A new fad: microdosing Ozempic.

What the Research Says About GLP-1 Therapy Clinical evidence behind GLP-1 medications is strong and still growing

The activated cPLA2 complex also binds to the lysosomal membrane and facilitates the release of enzymes that damage organelle membranes, leading to mitochondrial damage, organelle degradation and cell death associated with secondary injury [82]

Semaglutide (Wegovy) a licensed GLP-1 receptor agonist approved by the MHRA for weight management in eligible adults, as assessed in NICE technology appraisal TA875

SMGT-GLP-1 Nano Microneedle Patch has been certified by multiple national authorities

Additionally, the phenomenon of "Ozempic face" has emerged, highlighting the distressing facial changes that accompany the rapid and extensive weight loss induced by these medications

Over months, even minuscule impurities or inconsistencies in peptide sequencing can lead to variable results, unexpected immune responses, or a decline in efficacy